| 首页 | 证监局介绍 | 辖区监管动态 | 政务信息 | 办事服务 | | 辖区数据 互动交流 | | --- | --- | --- | --- | --- | --- | --- | | | ♀ 当前位置：首页 > 政务信息 > 主动公开 > 证监局文种体裁 > 行政监管措施 | | | | | | | 索 引 号 | bm56000001/2026-00000871 | | | | ਜੇ 崇 | 行政监管措施;证券经营机构监管 | | 发布机构 | | | | | 发文日期 | 2026年01月23日 | | 称 名 | 关于对浙商证券股份有限公司杭州分公司、林长富、应文敏采取出具警示函措施的决定 | | | | | | | 文 름 | | | | | 主题词 | | 北京商报讯（记者 刘宇阳）1月23日，浙江证监局发布公告表示，经查，浙商证券（601878）杭州分公司存在对投资者以往交易合规审核把关不严、账户实 名制管理不到位的问题，违反了相关规定。林长富、应文敏作为时任管理人员，对上述问题负有责任。 根据相关规定，浙江证监局决定对浙商证券杭州分公司、林长富、应文敏采取出具警示函的行政监管措施，并 ...

Investment Ratings - Banking: Overweight (Maintain) [1] - Securities: Market Weight (Maintain) [1] - Insurance: Overweight (Maintain) [2] Core Insights - The report highlights that the financing leverage is being actively adjusted, with the insurance preset interest rate stabilizing. The recent increase in margin requirements from 80% to 100% aims to promote long-term healthy development in the current market environment [2][47]. - The report indicates that the average margin balance has exceeded 2.7 trillion yuan in recent trading days, reflecting an accelerated pace of leveraged funds entering the market [2][47]. - The insurance preset interest rate research value for Q4 2025 is 1.89%, with a buffer of 14 basis points before triggering a downward adjustment [3][48]. Summary by Sections Market Review - As of January 22, 2026, the banking, securities, and insurance indices have experienced declines of -5.20%, -2.43%, and -7.46%, respectively, while the CSI 300 index decreased by -0.29% [11]. - Among the sub-sectors, Changshu Bank (+4.14%), Pacific Securities (+3.35%), and China Life (-4.29%) showed the best performance [11]. Valuation Situation - As of January 22, 2026, the PB ratio for the banking sector is 0.70, with state-owned banks, joint-stock banks, city commercial banks, and rural commercial banks having PB ratios of 0.75, 0.57, 0.69, and 0.61, respectively [21]. - The securities sector's PB valuation is 1.47, indicating potential for valuation recovery [25]. Recent Market Indicators - The 1-year MLF operation rate is 2.0%, with the 1-year and 5-year LPR at 3.0% and 3.50%, respectively [30]. - The average daily trading volume of A-shares is 26,971.78 billion yuan, showing a decrease of 21.33% compared to the previous week [36]. Industry News - The People's Bank of China has decided to lower the re-lending and re-discount rates by 0.25 percentage points to enhance the effectiveness of structural monetary policy tools [42]. - The China Insurance Industry Association held a meeting discussing the preset interest rates for life insurance products, confirming the current research value at 1.89% [42]. Company Announcements - Notable announcements include Ningbo Bank reporting a revenue of 71.968 billion yuan for 2025, a year-on-year increase of 8.01% [45]. - China Pacific Insurance reported a premium income of 258.115 billion yuan for 2025, reflecting an 8.1% growth [45]. Weekly Perspectives - The banking sector is advised to focus on regional banks with strong performance certainty, such as Ningbo Bank, Hangzhou Bank, and Changshu Bank [46]. - The securities sector is recommended to pay attention to firms with restructuring expectations, including Zheshang Securities and Guolian Minsheng [47]. - The insurance sector should focus on companies with leading premium growth, such as China Pacific Insurance and China Life [48].

Group 1: R&D Progress - DR10624 has shown strong lipid-lowering effects and safety in Phase II clinical trials, with results presented at the AHA Scientific Sessions 2025. It has been included as a breakthrough therapy for severe hypertriglyceridemia by the CDE in January 2026 [1][2] - HDM1002, an oral GLP-1 receptor agonist, has completed patient enrollment for its Phase III trial in weight management, with top-line data expected in Q3 2026. The study has shown good overall safety without liver enzyme elevation [3] - HDM2005 has reported positive preliminary results in Phase I trials for mantle cell lymphoma and classical Hodgkin lymphoma, and is also undergoing trials for diffuse large B-cell lymphoma and solid tumors [4] Group 2: Upcoming Data Releases - Key data releases expected in 2026 include: - HDM1002 weight management Phase III top-line data - HDM1005 weight management Phase III 40-week data - HDM2005 solid tumor Phase I preliminary data - DR10624 for MASLD/MASH Phase II top-line data [5] Group 3: New Product Approvals and Market Outlook - The company anticipates new drug approvals in 2026, including edaravone tablets and various biosimilars, which are expected to enhance revenue contributions [6][7] - The innovative products, such as Ailaha® and Huijiaojing®, are projected to maintain rapid growth due to their clinical value and market strategies [9] Group 4: Industrial Microbiology and Pet Medicine - The industrial microbiology sector is expected to continue its rapid growth, supported by expanding overseas markets and commercialized products [12] - The HDM7006 project for managing obesity in cats is addressing a significant market gap, with a reported obesity rate of 28.1% among pet cats in China. This product is positioned as a safe and effective GLP-1/GIP dual-target weight management solution [16] Group 5: Strategic Collaborations and Licensing - The company is actively pursuing licensing agreements for its self-developed products and is optimistic about future collaborations [8] - A strategic partnership with MC2 for skincare products aims to leverage innovative technology for daily skin care solutions in the Greater China region [14][15]

Investment Ratings - Banking: Overweight (Maintain) [1] - Securities: Market Weight (Maintain) [1] - Insurance: Overweight (Maintain) [1] Core Insights - The financial indices for banks, securities, and insurance have shown declines of -5.20%, -2.43%, and -7.46% respectively, while the CSI 300 index decreased by -0.29% during the same period [11] - The report indicates a marginal decrease in social financing growth, with December 2025 seeing an increase of 2.21 trillion yuan, which is a year-on-year decrease of 0.65 billion yuan [44] - The report highlights that the recent adjustment of margin requirements from 80% to 100% aims to promote long-term healthy development in the securities market [46] - The insurance sector's research value for the standard life insurance product interest rate is at 1.89%, with a buffer of 14 basis points before triggering a downward adjustment [47] Summary by Sections Market Review - As of January 22, 2026, the banking sector ranked last among 31 industries, with a decline of -5.20% [11] - Notable performers include Changshu Bank (+4.14%) and Pacific Securities (+3.35%), while China Life Insurance saw a decline of -4.29% [11] Financing and Credit - In December 2025, corporate bonds contributed significantly to social financing, with a year-on-year increase of 1.7 billion yuan [44] - The report indicates a decrease in household loans, reflecting a need for further stimulation in consumer spending and real estate purchases [44] Securities Insights - The increase in margin requirements is expected to lower leverage levels and guide funds towards rational participation in the market [46] - The average margin balance has exceeded 2.7 trillion yuan, indicating an uptick in leveraged trading activity [46] Insurance Insights - The current interest rate for standard life insurance products is stable, with a potential downward adjustment threshold set at 1.75% [47] - The report suggests that the 10-year government bond yield is stabilizing, reducing the likelihood of triggering the downward adjustment mechanism in the short term [47] Investment Recommendations - For banks, the report recommends focusing on regional banks with strong performance, such as Chengdu Bank and Ningbo Bank [44] - In the insurance sector, companies like China Pacific Insurance and Ping An are highlighted for their growth potential [47] - In the securities sector, firms like Zheshang Securities and CITIC Securities are recommended due to their strong fundamentals and market positioning [46]

维亚生物(01873)尾盘涨超18%，截至发稿，涨18.09%，报2.35港元，成交额6470.58万港元。 浙商证券（601878）此前指，展望来看，随着CRO端的AI应用项目占比持续提升以及CDMO重大商业 化项目的陆续落地，该行看好公司高盈利能力的趋势持续。国盛证券（002670）认为，整体来看，公司 通过CRO与CDMO的协同发展、AI驱动研发提效及投资孵化生态构建，有望持续受益于全球创新药产 业景气度提升，推动业绩稳健增长与长期价值释放。 消息面上，维亚生物公众号近日披露，1月13日，公司在第44届J.P.Morgan Healthcare Conference期间成 功举办Viva Biotech Innovation Forum2026。研讨会围绕人工智能与新药物类型的前沿进展展开了深入讨 论。其中，维亚生物就AI赋能多肽药物研发全流程实验设计以及AI赋能多肽CRDMO平台展开分享，集 中体现了人工智能如何在研发与产业化关键环节的加速落地，成为本次会议的重要看点。 ...

Group 1 - The core viewpoint is that the Federal Reserve's entry into a rate-cutting cycle may stimulate demand while simultaneously weakening the profits of pulp companies in Brazil, leading to supply control and driving pulp prices upward [2] - The industry is currently at a valuation and profit bottom, with paper prices at historical low percentiles and pulp prices also at low levels, indicating a safety margin for the sector [2] - The historical negative correlation between pulp prices and the US dollar index suggests that the Fed's rate cuts could be a key catalyst for price increases in the pulp market [2] Group 2 - Supply of commodity pulp is slowing, with limited new overseas capacity expected after 2025, and domestic self-sufficient pulp production is projected to add approximately 660 million tons from 2025 to 2026 [3] - Short-term demand remains resilient, with global hardwood pulp shipments expected to increase by 7% year-on-year, primarily driven by demand from China [4] - Current inventory levels are at a medium-low position, with global hardwood pulp producer inventory days at 44.7 days, indicating a strong price outlook for Q1 2026 [4] Group 3 - The cost of pulp varies significantly based on raw materials, with domestic pulp relying on imported wood chips having a cash cost of approximately $480 per ton, while using domestic wood chips can reduce costs to $420 per ton [4]

EDA行业：小市场撬动大生态，战略价值凸显 产业基石属性：EDA是半导体设计"刚需工具"，全球规模约157亿美元(2024年)，仅占半导体产业(6310 亿美元)的2.5%，但支撑数十万亿美元数字经济;先进制程下价值提升，28nm流片成本超1000万美元、 7nm近1亿美元，EDA直接决定流片成功率，成本权重持续上升。 智通财经APP获悉，浙商证券发布研报称，2022-2024年中国市场CAGR 10.55%，显著高于全球7.84%增 速，2030年预计突破500亿元。EDA处于国产替代突破关键时期，政策支持力度加大，龙头平台型企业 积极推动点工具并购整合，有望加速实现全流程覆盖。长期来看，国产化率及全球份额有望持续提升， 建议关注产业链核心标的长期投资价值。 浙商证券主要观点如下： 受益于半导体自主可控推进，我国EDA市场增速显著高于全球。但行业面临四大核心瓶颈：企业聚 焦"点工具"导致的碎片化竞争、资本扎堆上市可能加剧的整合难度、高端复合型人才数万人缺口、以及 国际"工具-工艺-设计"生态联盟形成的准入壁垒，制约国产EDA从"点状突破"向"系统性替代"跨越。 政策导向明确，整合协同推动产业升级 行业发展逻 ...

Core Insights - The surgical robot market is expected to grow significantly, with a projected market size exceeding 70 billion RMB and a CAGR of approximately 34% from 2024 to 2032, driven by increased penetration rates and the potential implementation of a fee schedule [1][2] Group 1: Market Potential - The overall market size for surgical robots in China is anticipated to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, reflecting a CAGR of about 34% [1] - The laparoscopic surgical robot market is expected to see a CAGR of around 29% during the same period, while the orthopedic surgical robot market may achieve a CAGR of approximately 41% [1] Group 2: Catalysts for Growth - The implementation of a fee schedule is identified as a key catalyst for the adoption of domestic surgical robots, with the market expected to enter a rapid development phase by 2026 [2] - The development cycle of domestic surgical robots is categorized into three phases: early development, rapid growth, and maturity, with the rapid growth phase expected to be triggered by improved product capabilities and clear reimbursement policies [2] Group 3: International Expansion - The overseas market for surgical robots is seen as a significant growth opportunity, with China's market currently representing only about 5% of the global market [3] - Several domestic companies, such as MicroPort and Precision Medical, are beginning to penetrate international markets, leveraging product advantages and innovations like 5G remote surgery [3] Group 4: Business Models - The business model of leading companies like Intuitive Surgical demonstrates a clear revenue generation strategy through a combination of systems, consumables, and services, with consumables and services accounting for 76% of revenue by 2024 [4][5] - The domestic laparoscopic surgical robot market is expected to follow a similar model, where device installations drive the growth of consumables and services [5] Group 5: Recommended Companies - Companies with strong commercialization capabilities and innovative production capacities are favored, including MicroPort, Meihua Medical, and Aikang Medical, with additional attention on Tianzhihang and Precision Medical [7]

Group 1 - As of January 22, 2025, five listed banks in A-shares have reported their preliminary performance for the year, showing an overall increase in net profit attributable to shareholders compared to 2024 [1] - Among these banks, three have reported a decrease in non-performing loan (NPL) ratios compared to the end of 2024 [1] - Shanghai Pudong Development Bank (SPDB) reported a revenue of 173.96 billion yuan, a year-on-year increase of 1.88%, and a net profit of 50.02 billion yuan, up 10.52% [1] - CITIC Bank and Industrial Bank reported revenues of 212.48 billion yuan and 212.74 billion yuan, with net profits of 70.62 billion yuan and 77.47 billion yuan, reflecting year-on-year growth of 2.98% and 0.34% respectively [1] - Ningbo Bank and Su Nong Bank also reported positive growth, with Ningbo Bank's revenue at 71.97 billion yuan (up 8.01%) and net profit at 29.33 billion yuan (up 8.13%), while Su Nong Bank's revenue was 4.19 billion yuan (up 0.41%) and net profit was 204.3 million yuan (up 5.04%) [1] Group 2 - Ningbo Bank disclosed its revenue structure, reporting net interest income of 53.16 billion yuan (up 10.77%) and net fee and commission income of 6.09 billion yuan (up 30.72%) [2] - All five listed banks have shown steady growth in total assets, with SPDB and CITIC Bank both surpassing 1 trillion yuan in total assets, reaching 1.008 trillion yuan and 1.013 trillion yuan respectively, marking increases of 6.55% and 6.28% from 2024 [2] - Industrial Bank's total assets reached 1.109 trillion yuan, up 5.57%, while Ningbo Bank's total assets grew by 16.11% to 363 billion yuan, and Su Nong Bank's total assets increased by 8% to 231.1 billion yuan [2] - In terms of asset quality, SPDB, CITIC Bank, and Su Nong Bank reported declines in NPL ratios, with ratios of 1.26%, 1.15%, and 0.88% respectively, while Ningbo Bank's NPL ratio remained stable and Industrial Bank's increased by 0.01 percentage points [2] Group 3 - The banking industry is expected to maintain stable performance in 2025, supported by significant improvements in funding costs, which are likely to stabilize net interest margins and boost interest income [3] - Analysts predict that the growth rates of revenue and net profit for listed banks in 2025 will improve compared to the first three quarters of 2025, driven by stable net interest margins and declining credit costs [3] - SPDB noted a significant decrease in interest costs, leading to a stabilization of net interest margins, while Ningbo Bank benefited from a 33 basis point drop in deposit interest rates, resulting in substantial growth in interest income [3] - The effects of previous reductions in deposit rates are expected to continue into 2026, helping to improve funding costs and reduce pressure on net interest margins, indicating a potential recovery phase [3]

转自：经济日报 1月20日，海外市场迎来2026年第一场"巨震"——"抛售美国"交易卷土重来、日债收益率历史性迈入"4 时代"、全球债市遭遇"抛售潮"、权益等风险资产普跌…… 分析人士普遍认为，地缘紧张局势、关税忧虑及日债"抛售潮"的连锁反应共同构成了本次海外市场震荡 的核心逻辑，也暴露出发达经济体普遍的财政可持续性隐忧。展望后市，仍需关注政策演变等关键信 号。 美国市场"股债汇三杀" （来源：经济日报） 渣打中国财富方案部首席投资策略师王昕杰对上证报记者表示，本轮海外市场波动的"震源"来自日本。 日本国债遭遇历史性抛售，收益率提高导致全球套息交易的平仓，作为资产端的美债被抛售，实际上是 套息交易当中的逻辑联动。 "日美投资者之间存在较强的跨境联动效应。因此，当美债与日债同时出现抛售压力时，极易形成跨市 场的负面反馈循环，加剧波动。"林成炜称。 "美国信用"下滑加速了这一趋势。王昕杰表示，2026年的宏观核心议题在于，主要经济体在货币政策空 间受限的背景下，财政政策捉襟见肘，日本面临的是投资者对于日本财政的信任度下降，美国则需应对 在套息交易大规模平仓过程中的"美国信用"下滑问题。 这反映出美国、欧洲、日本等 ...